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Acid inhibitory therapy has long been considered of no benefit for upper GI
bleeding. The reason was that achlorhydria in the stomach could notbe achieved
with any single or combination of acid inhibitory drugs. The introduction of
proton pump inhibitors has, for the first time, allowed the physician to tem-
porarily achieve achlorhydria by large doses of intravenously applied proton
pump inhibitors. The first placebo-controlled clinical trials have shown that,
indeed, an intragastric pH of near 7 can significantly improve the clinical out-
come of upper GI bleeding. Pharmacokinetic studies with proton pump
inhibitors have shown that a bolus of 80 mg pantoprazole or omeprazole fol-
lowed by immediate continuous infusion ofeight mg per hour will result in an
intragastric pH of 7 within 20 minutes. This intragastric pH optimizes the dif-
ferent steps ofhemostasis in the stomach.
INTRODUCTION
For decades, physicians have tried to influenice intragastric bleeding by physical and
pharmacological means. No significant influence by the many approaches could be
achieved until recent endoscopic techniques brought a breakthrough by stopping the
active bleeding by means ofinjection ofvasoconstricting and sclerosing agents or by heat
coagulation [1-6]. Through these techniques, emergency surgery has been significantly
reduced. However, after initial endoscopic hemostasis, rebleeding still occurs in up to 20
percent ofpatients, and surgery is still necessary in some of these patients.
Optimization ofthephysiological conditions forhemostasis has been the aim ofmany
pharmacological approaches. None ofthese approaches has resulted in convincing effects.
Reduction ofblood flow was one ofthese approaches for which vasopressin, somatostatin
and secretin have been applied [7-11]. Pepsin inhibitors were introduced with the aim of
preventing clot digestion [12]. Inhibition of thrombolysis was tried by the application of
tranexamic acid [13]. This method was so successful that notonly thrombolysis was inhib-
ited, but thrombosis appeared in many parts of the body preventing further use of this
approach. Increasing intragastric pH was the final pharmacological approach, which also
yielded disappointing results. Antacids, anticholenergics and histamine receptor antago-
nists were without effects because they could not reliably achieve that elevation of the
intragastric pH that is necessary to significantly influence the physiology of hemostasis
[14, 15, 16]. The failure of the H2-receptor antagonists is explained by the rapid onset of
tolerance towards these drugs [17-19].
Green and coworkers have shown that platelet aggregation and blood coagulation are
optimal at pH 7.4. Below pH 5.9, platelet aggregation, the initial step of hemostasis, is
practically non-existent [20]. Freshly formed clots can easily be digested by gastric pepsin
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as long as there is any acid left in the stomach [21]. The physiology of hemostasis
demands pH values near 7. Only proton pump inhibitors can reliably achieve such values
ifsufficientdoses are given. In early studies with intravenous omeprazole forpeptic bleed-
ing, insufficient doses were used. But even these doses showed significant improvement
over H2-receptor antagonist therapy [22, 23]. Pharmacokinetic studies with omeprazole
concluded that an initial bolus injection of 80 mg followed by a continuous infusion of
eight mg per hour was optimal with regard to reduction ofintragastric acidity [24, 25, 26].
This dosage regimen was investigated in two large placebo-controlled trials and revealed
a significant advantage for the omeprazole therapy with respect to frequency of surgery,
need for the endoscopic interventions, the severity and the duration ofbleeding, as well as
the need for blood transfusions [27, 28].
The aim of this study was to investigate the optimal mode of application and dosing
ofintravenously administered pantoprazole, a new proton pump inhibitor.
SUBJECTS AND METHODS
Medication
The pantoprazole i.v. formulation (Byk Gulden, Konstanz, Germany) was diluted
using 0.9 percent NaCl solution and administered as a dilution offour mg/hr. Bolus injec-
tions of40 mg (10 ml) or 80 mg (20 ml) were administered within two minutes; the long-
term infusions were given at a rate of one ml/hr (four mg/hr) or two ml/hr (eight mg/hr).
Doses stated in mg refer to pantoprazole as the free acid; the drug, however, was admin-
istered as the sodium salt.
Dietary
The subjects took their last meal at 6:00 p.m. the day prior to the investigation and
remained fasting throughout the treatment period on the next day. Drinking of water was
allowed.
pH metry
Intragastric pH was continuously recorded using Digitrappers MKII/MKIII
(Synectics Medical, Stockholm, Sweden) and glass electrodes M440 (Ingold, Urdorf,
Switzerland). The electrodes were calibrated before use at pH 1 and 7 using commercial-
ly available buffers. The probe was inserted into the nose and moved downward until the
pH turned from neutral to acid (when passing the cardia). The probe was then pushed for-
ward another six cm and fixed at the nose.
Laboratory
Laboratory values were determined directly before and one day after the investiga-
tion; these included routine hematologic studies, assay of serum enzymes indicative of
liver function, serum electrolyte measurements, and serum creatinine determination.
SUBJECTS
Repeated bolus injections
Eight healthy volunteers (four males; four females) were admitted to the study. Six
subjects completed the study protocol correctly. Their ages ranged from 26 to 42 years,
and their body weights were between 50 and 80 kg. Each of them underwent a treatment
period of48 hours with eight hourly bolus injections of40 mg each, preceded by a load-
ing dose of 80 mg (bolus) in the beginning. Intragastric pH was continuously recorded
over 48 hours.
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Long-term infusion (four mg/hr)
Six healthy volunteers (three males; three females), with ages ranging from 24 to 30
years and body weights between 60 and 80 kg, underwent two treatment periods of 48
hours each in randomized order under double-blind conditions. In one period, a loading
dose of 40 mg (bolus) was administered, subsequently followed by a long-term infusion
of four mg/hr. In the other period, placebo (0.9 percent NaCl solution) was administered
instead ofpantoprazole. Intragastric pH was continuously recorded over 48 hours in both
periods.
Long-term infusion (eight mg/hr)
Eight healthy volunteers (four males; four females), with ages ranging from 25 to 32
years and body weights between 50 and 76 kg, underwent two treatment periods of 24
hours each in randomized order. In both periods, separated by a wash-out interval of at
least one week, a long-term infusion ofeight mg/hr was administered. In one period, the
loading dose of 80 mg was given as a bolus injection, in the other period it was given as
a two-hour infusion (the latter means that the infusion rate was 48 mg/hr during the first
two hours).
RESULTS
Intragastric Acidity
The median 24 hour profiles of intragastric pH for the four different modes of appli-
cation are shown in Figures 1 to 3. All doses caused a significant reduction ofintragastric
acidity.
The percentage of time with an intragastric pH above 3, 4, 5 and 6 is shown in Table
1. Intermittent bolus injections do not significantly raise the pH above 3.0 (Figure 1).
Continuous infusion with a significantly lower total 24-hour dose is more effective in
increasing the intragastric pH, showing an improvement on the second day of infusion
(Figure 2). Doubling the hourly infusion rate to eight mg per hour achieves the desired
breakthrough (Figure 3). There is amarked difference between the effect ofthe two differ-
ent loading doses. Spreading the loading dose of 80 mg over two hours results in a retard-
ed pH increase, reaching the optimal pH only after 12 hours. Applying the initial loading
dose as a bolus given within two minutes achieves the desired pH within 20 minutes
(Figure 3). The optimal mode ofapplication for reaching the intragastric pH necessary for
Table 1. Comparison offour differentmodesofpantoprazoleapplication with respect tomedi-
an percent time above pH 3.0, 4.0, 5.0 and 6.0.
Infusion Infusion Infusion
40 mg bolus 4 mg/hr 8 mg/hr 8 mg/hr
Median percent every 40 mg initial 48 mg/hr 80 mg initial
time above Placebo 8 hours bolus initial 2 hours bolus
Day I Day 2 Day I Day 2 Day I Day 2
pH 3.0 22 6 49 78 88 100 94 99
pH4.0 7 0 20 47 54 85 82 99
pH 5.0 1 0 5 16 24 42 55 94
pH 6.0 1 0 0 1 13 10 31 84
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Figure 1. Median intragastric pH profile in healthy subjects (n = 6) after an initial bolus of80
mg pantoprazole followed by eight hourly bolus doses of40 mg pantoprazole.
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Figure 2. Median intragastric pH profile in healthy subjects receiving continuous infusion of
placebo (thin line) or 40 mg bolus injection of pantoprazole followed by continuous infusion
offour mg/hr pantoprazole (thick line) (n = 6).
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Figure 3. Median intragastric pH profile in healthy subjects (n = 8) receiving an infusion of
eight mg/hr pantoprazole after an initial loading dose of 48 mg/hr pantoprazole for the first
two hours or eight mg/hr pantoprazole after a rapid bolus of80 mg pantoprazole (n = 7).
a physiological hemostasis is, therefore, a rapid bolus of 80 mg pantoprazole followed by
an infusion ofeight mg pantoprazole per hour.
Tolerability
Pantoprazole was well-tolerated by the subjects. No clinically significant changes in
the electrocardiograms or laboratory tests were found. Adverse experiences were few and
none was considered clinically important or related to drug exposure.
DISCUSSION
The results clearly show that a rapid increase of the intragastric pH above 6 can be
reliably achieved only by continuous infusion with a large initial bolus dose. Spreading
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the bolus over a time of two hours delays the maximum pH effect by 12 hours. With the
lower infusion rate of four mg/hr, a pH above 6 is also eventually achieved. But this will
take some time and therefore is not suitable foremergency application. However, this dose
may well be used as a maintenance dose, once a desired intragastric pH has been reached
[25]. Intermittent bolus application cannot achieve the necessary intragastric pH because
proton pumps are continuously being regenerated [29]. This implies that a proton pump
inhibitor should be continuously available in the circulation to inhibit newly generated
pumps and thereby inhibit gastric acidity for prolonged periods. In healthy subjects the
half-life of proton pump inhibitors in the circulation is approximately 60 minutes. Since
it takes four half-lives for a drug to be effectively eliminated from the circulation, bolus
injections would have to be given every two to three hours in order to keep sufficient drug
in the circulation. Such investigations have notyet been carried out and this mode ofappli-
cation would appear to be very impracticable for clinical use. Currently, continuous infu-
sion is easy to apply and to control.
These data found for pantoprazole are almost identical with those that we and other
investigators have found for omeprazole [24, 25, 26]. Both drugs seem to be equivalent
when given intravenously.
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